JP2007527406A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007527406A5 JP2007527406A5 JP2006526305A JP2006526305A JP2007527406A5 JP 2007527406 A5 JP2007527406 A5 JP 2007527406A5 JP 2006526305 A JP2006526305 A JP 2006526305A JP 2006526305 A JP2006526305 A JP 2006526305A JP 2007527406 A5 JP2007527406 A5 JP 2007527406A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- godan
- binding
- hmgb
- piece
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 37
- 108090001123 antibodies Proteins 0.000 claims 37
- 239000000427 antigen Substances 0.000 claims 26
- 102000038129 antigens Human genes 0.000 claims 26
- 108091007172 antigens Proteins 0.000 claims 26
- 210000004408 Hybridomas Anatomy 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000002222 HMGB1 Protein Human genes 0.000 claims 12
- 108010014739 HMGB1 Protein Proteins 0.000 claims 12
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 8
- 102000005614 monoclonal antibodies Human genes 0.000 claims 7
- 108010045030 monoclonal antibodies Proteins 0.000 claims 7
- 206010003246 Arthritis Diseases 0.000 claims 3
- 206010025135 Lupus erythematosus Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 230000002757 inflammatory Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 108009000283 Allograft Rejection Proteins 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 208000009137 Behcet Syndrome Diseases 0.000 claims 1
- 201000008335 Behcet's disease Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 206010018651 Graft versus host disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 claims 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010061255 Ischaemia Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010034674 Peritonitis Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000000890 antigenic Effects 0.000 claims 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 230000001809 detectable Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960000060 monoclonal antibodies Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 230000001568 sexual Effects 0.000 claims 1
Claims (20)
- (a)ATCC受託番号PTA-5433で寄託されている6E6 HMGB1 mAb、
(b)ATCC受託番号PTA-5434で寄託されている6H9 HMGB1 mAb、
(c)ATCC受託番号PTA-5432で寄託されている2G7 HMGB1 mAb、
(d)ATCC受託番号PTA-5435で寄託されている10D4 HMGB1 mAbおよび
(e)ATCC受託番号PTA-5431で寄託されている2E11 HMGB1 mAb
からなる群より選択されるマウスハイブリドーマにより産生される抗体、またはその抗原結合断片。 - (a)ATCC受託番号PTA-5433で寄託されている6E6 HMGB1 mAb、
(b)ATCC受託番号PTA-5434で寄託されている6H9 HMGB1 mAb、
(c)ATCC受託番号PTA-5432で寄託されている2G7 HMGB1 mAb、
(d)ATCC受託番号PTA-5435で寄託されている10D4 HMGB1 mAbおよび
(e)ATCC受託番号PTA-5431で寄託されている2E11 HMGB1 mAb
からなる群より選択されるマウスハイブリドーマ。 - 配列番号1のアミノ酸残基61〜78または67〜78からなるペプチドと結合する、単離されたモノクローナル抗体または抗原結合断片。
- 配列番号1のアミノ酸残基61〜78または67〜78からなるペプチドへの結合が6E6 HMGB1 mAbおよび6H9 HMGB1 mAbからなる群より選択される抗体によって阻害され得る、単離されたモノクローナル抗体または抗原結合断片。
- 請求項2記載のマウスハイブリドーマにより産生される抗体の軽鎖CDR (CDR1、CDR2およびCDR3)ならびに重鎖CDR (CDR1、CDR2およびCDR3)を含有する、単離されたモノクローナル抗体またはその抗原結合断片。
- ヒトフレームワーク領域をさらに含有する、請求項1、3、4もしくは5記載の抗体またはその抗原結合断片。
- 請求項6記載の抗体または抗原結合断片および薬学的に許容され得る賦形剤を含有してなる組成物。
- 請求項2記載のマウスハイブリドーマにより産生されるモノクローナル抗体またはその抗原結合断片および薬学的に許容され得る賦形剤を含有してなる組成物。
- i)請求項2記載のマウスハイブリドーマにより産生される抗体;
ii)請求項2記載のマウスハイブリドーマにより産生される抗体のエピトープ特異性を有する抗体;
iii)請求項2記載のマウスハイブリドーマにより産生される抗体と、脊椎動物高移動度グループボックス(HMGB)ポリペプチドへの結合に関して競合し得る抗体;または
iv)i)、ii)もしくはiii)の抗原結合断片
である、単離されたモノクローナル抗体またはその抗原結合断片。 - ヒト抗体、ヒト化抗体、キメラ抗体および前記いずれかの抗原結合断片からなる群より選択される、請求項9記載の抗体または抗原結合断片。
- i) HMGBに結合するモノクローナル抗体またはその抗原結合断片;
ii) 試験薬剤;および
iii) 脊椎動物HMGBポリペプチドを含有してなる組成物
を合わせる工程;
ならびに前記抗体または抗原結合断片と前記HMGBポリペプチドとの複合体の形成を検出または測定する工程を含み、ここで、適当な対照と比べた前記複合体の形成の減少は、前記試験薬剤が前記HMGBポリペプチドに結合することを示し、
前記モノクローナル抗体またはその抗原結合断片が、
i)請求項2記載のマウスハイブリドーマにより産生される抗体;
ii)請求項2記載のマウスハイブリドーマにより産生される抗体のエピトープ特異性を有する抗体;
iii)請求項2記載のマウスハイブリドーマにより産生される抗体と、脊椎動物高移動度グループボックス(HMGB)ポリペプチドへの結合に関して競合し得る抗体;または
iv)i)、ii)もしくはiii)の抗原結合断片
である、脊椎動物高移動度グループボックス(HMGB)ポリペプチドに結合する薬剤の検出および/または同定方法。 - 被験体において、炎症性サイトカインカスケードの活性化を特徴とする状態の処置、または敗血症、関節炎もしくは狼瘡を有する被験体の処置のための医薬の製造のための、
i)請求項2記載のマウスハイブリドーマにより産生される抗体;
ii)請求項2記載のマウスハイブリドーマにより産生される抗体のエピトープ特異性を有する抗体;
iii)請求項2記載のマウスハイブリドーマにより産生される抗体と、脊椎動物高移動度グループボックス(HMGB)ポリペプチドへの結合に関して競合し得る抗体;または
iv)i)、ii)もしくはiii)の抗原結合断片の使用。 - 前記状態が、敗血症、同種移植拒絶、関節炎、喘息、狼瘡、成人呼吸促進症候群、慢性閉塞性肺疾患、乾癬、膵臓炎、腹膜炎、熱傷、虚血、ベーチェット病、対宿主性移植片病、炎症性腸疾患、多発性硬化症および悪液質からなる群より選択される、請求項12記載の使用。
- 被験体において、炎症性サイトカインカスケードの活性化を特徴とする状態の処置の、または敗血症、関節炎もしくは狼瘡の処置における使用のための、
i)請求項2記載のマウスハイブリドーマにより産生される抗体;
ii)請求項2記載のマウスハイブリドーマにより産生される抗体のエピトープ特異性を有する抗体;
iii)請求項2記載のマウスハイブリドーマにより産生される抗体と、脊椎動物高移動度グループボックス(HMGB)ポリペプチドへの結合に関して競合し得る抗体;または
iv)i)、ii)もしくはiii)の抗原結合断片。 - a) 試料を、請求項9記載の抗体または抗原結合断片と、前記試料中に存在する前記HMGBポリペプチドへの前記抗体または抗原結合断片の結合に適した条件下で接触させる工程;および
b) 抗体-HMGB複合体または抗原結合断片-HMGB複合体を検出する工程
を含み、
ここで、前記抗体-HMGB複合体または抗原結合断片-HMGB複合体の検出は、前記試料中のHMGBポリペプチドの存在を示す、
試料中の脊椎動物高移動度グループボックス(HMGB)ポリペプチドの検出方法。 - 前記抗体または抗原結合断片が、請求項2記載のマウスハイブリドーマにより産生されるか、または前記いずれかの抗原結合断片である、請求項15記載の方法。
- 前記抗体または抗原結合断片が検出可能な標識を含有する、請求項15記載の方法。
- 前記抗体-HMGB複合体または抗原結合断片-HMGB複合体の検出が、イムノアッセイによるものである、請求項15記載の方法。
- 前記イムノアッセイがELISAである、請求項18記載の方法。
- a) 請求項9記載の抗体または抗原結合断片;および
b) 前記抗体または抗原結合断片と前記HMGBポリペプチドまたはその部分との複合体の存在の検出に適した1種類以上の補助試薬
を含む、試料中の脊椎動物高移動度グループボックス(HMGB)ポリペプチドまたはその部分の存在の検出における使用のための試験キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50256803P | 2003-09-11 | 2003-09-11 | |
US60/502,568 | 2003-09-11 | ||
PCT/US2004/029527 WO2005026209A2 (en) | 2003-09-11 | 2004-09-10 | Monoclonal antibodies against hmgb1 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011118559A Division JP5513441B2 (ja) | 2003-09-11 | 2011-05-27 | Hmgb1に対するモノクローナル抗体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007527406A JP2007527406A (ja) | 2007-09-27 |
JP2007527406A5 true JP2007527406A5 (ja) | 2007-11-08 |
JP4792392B2 JP4792392B2 (ja) | 2011-10-12 |
Family
ID=34312406
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006526305A Expired - Fee Related JP4792392B2 (ja) | 2003-09-11 | 2004-09-10 | Hmgb1に対するモノクローナル抗体 |
JP2011118559A Expired - Fee Related JP5513441B2 (ja) | 2003-09-11 | 2011-05-27 | Hmgb1に対するモノクローナル抗体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011118559A Expired - Fee Related JP5513441B2 (ja) | 2003-09-11 | 2011-05-27 | Hmgb1に対するモノクローナル抗体 |
Country Status (7)
Country | Link |
---|---|
US (4) | US7288250B2 (ja) |
EP (1) | EP1668035A2 (ja) |
JP (2) | JP4792392B2 (ja) |
CN (1) | CN1878793A (ja) |
AU (1) | AU2004272607B2 (ja) |
CA (2) | CA2882022A1 (ja) |
WO (1) | WO2005026209A2 (ja) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
US7304034B2 (en) * | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
AU2004272607B2 (en) * | 2003-09-11 | 2008-11-06 | Cornerstone Therapeutics Inc. | Monoclonal antibodies against HMGB1 |
EP1717250A4 (en) * | 2004-02-20 | 2008-10-01 | Immuno Biological Lab Co Ltd | MONOCLONAL ANTIBODY AND ITS USE |
US20080305120A1 (en) * | 2004-06-17 | 2008-12-11 | Medimmune, Inc. | Immunogenic Compositions Comprising Hmgb 1 Polypeptides |
US7470521B2 (en) | 2004-07-20 | 2008-12-30 | Critical Therapeutics, Inc. | RAGE protein derivatives |
US8129130B2 (en) | 2004-10-22 | 2012-03-06 | The Feinstein Institute For Medical Research | High affinity antibodies against HMGB1 and methods of use thereof |
CA2585043A1 (en) * | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
AU2005313971B2 (en) * | 2004-12-08 | 2011-10-13 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
US20100040607A1 (en) * | 2005-05-13 | 2010-02-18 | Tracey Kevin J | Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases |
US8354106B2 (en) | 2005-06-16 | 2013-01-15 | The Feinstein Institute For Medical Research | Antibodies against HMGB1 and fragments thereof |
WO2007011606A2 (en) * | 2005-07-18 | 2007-01-25 | Critical Therapeutics, Inc. | USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS |
JP5376948B2 (ja) | 2005-09-13 | 2013-12-25 | ナショナル リサーチ カウンシル オブ カナダ | 腫瘍細胞活性を調節する方法及び組成物 |
WO2007031100A1 (en) * | 2005-09-14 | 2007-03-22 | Ostini, Marco | Active immunotherapy of life-threatening systemic inflammation |
JP3876325B1 (ja) * | 2005-10-24 | 2007-01-31 | 国立大学法人 岡山大学 | 脳梗塞抑制剤 |
US20100172909A1 (en) * | 2005-10-24 | 2010-07-08 | Masahiro Nishibori | Cerebral edema suppressant |
US20080311122A1 (en) * | 2005-11-28 | 2008-12-18 | Medimmune, Llc | Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof |
JP3882090B1 (ja) * | 2006-05-19 | 2007-02-14 | 国立大学法人 岡山大学 | 脳血管攣縮抑制剤 |
CN1850863B (zh) * | 2006-05-23 | 2012-07-04 | 中国科学院生物物理研究所 | 针对自身抗原和/或种属间高度保守抗原的抗体及其制备方法 |
JP4982739B2 (ja) * | 2006-06-01 | 2012-07-25 | 国立大学法人 東京医科歯科大学 | ポリグルタミン病の予防・治療剤 |
JP5382570B2 (ja) * | 2006-12-20 | 2014-01-08 | 株式会社シノテスト | ヒトhmgb1と特異的に結合する鳥類由来の抗体、ヒトhmgb1の免疫学的測定方法及びヒトhmgb1の免疫学的測定試薬 |
JP5225109B2 (ja) * | 2007-02-15 | 2013-07-03 | 国立大学法人 熊本大学 | ヒトhmgb−1に特異的に結合する抗体を有効成分として含有する治療剤 |
US20100173277A1 (en) * | 2007-02-15 | 2010-07-08 | Fukuoka University | Agent for Suppressing Rejection in Organ Transplantation Comprising Anti-HMGB-1 Antibody |
TW200900077A (en) | 2007-02-15 | 2009-01-01 | Univ Kyushu Nat Univ Corp | Therapeutic agent for interstitial pulmonary disease comprising anti-HMGB-1 antibody |
WO2009133943A1 (ja) | 2008-04-30 | 2009-11-05 | 株式会社ジェノミックス | 生体内機能的細胞の高効率採取法 |
ITMI20080799A1 (it) * | 2008-04-30 | 2009-11-01 | Areta Internat S R L | Anticorpi monoclonali amti hmga1 procedimento per la loro preparazione e loro impiego per la determinazione quantitativa di hmga1 |
CN102209897B (zh) * | 2008-09-11 | 2015-04-29 | 巴斯德研究院 | 通过调节hiv-1复制和顽固存在的hmgb1依赖性触发来监测和抑制人免疫缺陷病毒感染 |
CN101891817B (zh) * | 2009-03-03 | 2012-11-07 | 中国科学院生物物理研究所 | 抗高迁移率族蛋白b-1的单克隆抗体及其应用 |
CN101798347B (zh) * | 2009-03-03 | 2012-05-30 | 中国科学院生物物理研究所 | 抗高迁移率族蛋白b1的单克隆抗体 |
NZ596136A (en) * | 2009-05-08 | 2013-12-20 | Vaccinex Inc | Anti-cd100 antibodies and methods for using the same |
WO2011007876A1 (ja) * | 2009-07-16 | 2011-01-20 | Necソフト株式会社 | Hmgb1結合核酸分子およびその用途 |
JP2011095014A (ja) * | 2009-10-27 | 2011-05-12 | Canon Inc | 免疫学的測定方法及び免疫学的測定キット |
CA2778759A1 (en) | 2009-10-28 | 2011-05-05 | Genomix Co., Ltd. | Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood |
US8802826B2 (en) | 2009-11-24 | 2014-08-12 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
KR20120123299A (ko) | 2009-12-04 | 2012-11-08 | 제넨테크, 인크. | 다중특이적 항체, 항체 유사체, 조성물 및 방법 |
EP2365332B1 (en) | 2010-03-10 | 2013-05-29 | Institut Pasteur | HMGB1 and anti-HMGB1 antibodies in HIV infected patients especially with neurological disorders |
US8999349B2 (en) | 2010-07-27 | 2015-04-07 | The Regents Of The University Of California | HMGB1-derived peptides enhance immune response to antigens |
CN102375064A (zh) * | 2010-08-26 | 2012-03-14 | 杭州华得森生物技术有限公司 | 用酶联免疫法检测人体中hmga2含量的体外诊断试剂盒 |
WO2012074043A1 (ja) * | 2010-12-03 | 2012-06-07 | 国立大学法人 岡山大学 | 外傷性神経障害治療剤 |
EP2694548B1 (en) * | 2011-04-05 | 2015-12-02 | Dia.pro Diagnostic Bioprobes S.r.l. | Hmgb1 specific monoclonal antibodies |
DK3358011T3 (da) | 2011-04-26 | 2020-05-11 | Univ Osaka | Peptid til inducering af regenerering af væv og anvendelse deraf |
US9561274B2 (en) * | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
EP2756002A4 (en) * | 2011-09-16 | 2015-04-08 | Univ Texas | COMPOSITIONS AND METHODS RELATED TO THE REPAIR OF DNA INJURY |
CA2851805C (en) | 2011-10-11 | 2021-12-28 | Vaccinex, Inc. | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
GB2504139B (en) * | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
WO2013091903A1 (en) * | 2011-12-22 | 2013-06-27 | Novo Nordisk A/S | Anti-crac channel antibodies |
JP2015512877A (ja) | 2012-02-22 | 2015-04-30 | アレシア・バイオセラピューティクス・インコーポレーテッド | 癌を治療するためのクラステリン阻害剤とegfr阻害剤の併用 |
US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
CN102924577B (zh) * | 2012-11-28 | 2014-03-26 | 扬州大学 | 鸡高迁移率族蛋白b1抗原多肽和抗鸡高迁移率族蛋白b1单克隆抗体 |
BR112015018035A2 (pt) * | 2013-01-28 | 2017-11-21 | Evec Inc | anticorpo anti-hmgb1 humanizado ou seu fragmento que se liga ao antígeno |
US9840555B2 (en) | 2013-11-04 | 2017-12-12 | Li-Te Chin | Method for producing human monoclonal antibodies that binds to at least one part of HMGB1 |
US10040862B2 (en) | 2014-04-18 | 2018-08-07 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to CD99 |
KR101689540B1 (ko) * | 2014-07-04 | 2016-12-27 | 한양대학교 산학협력단 | 세포 이식 거부반응 억제용 약제학적 조성물 |
EP3341411A1 (en) * | 2015-08-28 | 2018-07-04 | Alector LLC | Anti-siglec-7 antibodies and methods of use thereof |
AR108688A1 (es) | 2016-05-03 | 2018-09-19 | Univ Arkansas | Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso |
US20190284259A1 (en) * | 2016-07-22 | 2019-09-19 | Georgia State University Research Foundation | Monoclonal Antibodies to B Virus And Their Use For Identification Of B Virus Specific Reactive Peptides |
US10730937B2 (en) | 2016-08-09 | 2020-08-04 | National University Corporation Tokyo Medical And Dental University | Antibodies against HMB1, and composition comprising same for treating or preventing alzheimer's disease |
WO2018057755A1 (en) * | 2016-09-21 | 2018-03-29 | Thorne Stephen H | High mobility group box i mutant |
US11174310B2 (en) | 2016-10-26 | 2021-11-16 | Fuso Pharmaceutical Industries, Ltd. | Disulfide-type HMGB1-specific antibody, method for measuring disulfide-type HMGB1 and kit for said measurement, and measurement method capable of quantitating all of HMGB1 molecules including reduced HMGB1, disulfide-type HMGB1 and thrombin-cleavable HMGB1 and kit for said measurement |
WO2018139562A1 (ja) | 2017-01-27 | 2018-08-02 | 株式会社ジェノミックス | 心筋症、陳旧性心筋梗塞および慢性心不全の治療薬 |
WO2019048040A1 (en) * | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
WO2019107530A1 (ja) | 2017-12-01 | 2019-06-06 | 株式会社ステムリム | 炎症性腸疾患の治療薬 |
CN109957015A (zh) * | 2019-04-01 | 2019-07-02 | 中国人民解放军海军军医大学国家肝癌科学中心 | 一种hmgb1封闭性抗体的制备方法及其应用 |
EP3875118A4 (en) * | 2019-12-18 | 2022-04-27 | National University Corporation Okayama University | USE OF ANTIBODY-DRUG CONJUGATES AND ANTIBODIES FOR DRUG DELIVERY |
EP4126245A4 (en) * | 2020-03-31 | 2024-05-08 | Fred Hutchinson Cancer Center | ANTI-CD33 ANTIBODIES AND THEIR USES |
AU2021264094A1 (en) * | 2020-04-30 | 2022-11-24 | Board Of Regents, The University Of Texas System | Anti-CD79b antibodies and chimeric antigen receptors and methods of use thereof |
CN115956089A (zh) | 2020-05-04 | 2023-04-11 | 加利福尼亚大学董事会 | 抑制性抗enpp1抗体 |
EP4178626A2 (en) * | 2020-07-13 | 2023-05-17 | University of Southern California | Universal car-nk cell targeting various epitopes of hiv-1 gp160 |
CN113151186B (zh) * | 2021-02-04 | 2022-02-18 | 上海交通大学 | 抗人cd271的单克隆抗体及用途 |
CA3215344A1 (en) | 2021-04-30 | 2022-11-03 | Kalivir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
CN113203857B (zh) * | 2021-05-06 | 2021-12-31 | 上海奕检医学检验实验室有限公司 | 一种肿瘤诊断试剂盒 |
WO2023137291A1 (en) * | 2022-01-11 | 2023-07-20 | Board Of Regents, The University Of Texas System | Anti-cd94 antibody and chimeric antigen receptor and methods of use thereof |
KR20230139195A (ko) * | 2022-03-25 | 2023-10-05 | 부산대학교 산학협력단 | 신규한 hmgb1 유래 펩타이드 및 이의 용도 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6468A (en) * | 1849-05-22 | ruteyen | ||
US4678772A (en) * | 1983-02-28 | 1987-07-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions containing glycyrrhizin |
JPS6032714A (ja) * | 1983-08-01 | 1985-02-19 | Teijin Ltd | 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物 |
US5585344A (en) * | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
JPS62166897A (ja) | 1986-01-20 | 1987-07-23 | Toyo Soda Mfg Co Ltd | 核内非ヒストン蛋白質に対するモノクロ−ナル抗体 |
JPS63135351A (ja) * | 1986-11-28 | 1988-06-07 | Sanwa Kagaku Kenkyusho Co Ltd | グリチルレチン酸誘導体、その製法及び該化合物を有効成分とする抗潰瘍剤 |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
JP2998287B2 (ja) * | 1991-03-13 | 2000-01-11 | 千寿製薬株式会社 | グリチルレチン酸誘導体 |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
DE69233782D1 (de) | 1991-12-02 | 2010-05-20 | Medical Res Council | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
IT1253431B (it) | 1991-12-02 | 1995-08-08 | Valetudo S R L | Preparati farmaceutici per uso topico destinati al trattamento della psoriasi e della dermatite atopica |
IT1254321B (it) * | 1992-04-10 | 1995-09-14 | Kemiprogress S R L | Composizione farmaceutica per il trattamento e la prevenzione delle infiammazioni cutanee e della mucosa orale. |
GB9217316D0 (en) * | 1992-08-14 | 1992-09-30 | Ludwig Inst Cancer Res | Schwann cell mitogenic factor,its preparation and use |
EP0727487A1 (en) | 1995-02-17 | 1996-08-21 | K.U. Leuven Research & Development | Multiple-tumor aberrant growth genes |
JP3472048B2 (ja) | 1995-10-09 | 2003-12-02 | 鐘淵化学工業株式会社 | 自己免疫疾患の診断薬 |
DE19548122A1 (de) | 1995-12-21 | 1997-06-26 | Joern Prof Dr Bullerdiek | Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben |
US6323329B1 (en) | 1995-12-21 | 2001-11-27 | Jorn Bullerdiek | Nucleic acid sequences of genes encoding high mobility group proteins |
US5864018A (en) * | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
US6720472B2 (en) * | 1996-07-12 | 2004-04-13 | University Of Medicine And Dentistry Of New Jersey | HMGI proteins in cancer and obesity |
US6171779B1 (en) * | 1996-07-12 | 2001-01-09 | University Of Medicine & Dentistry Of New Jersey | HMGI proteins in cancer |
CA2262443A1 (en) | 1996-07-17 | 1998-01-22 | Kaneka Corporation | Diagnostic drugs for autoimmune diseases |
US7258857B2 (en) * | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
WO2000020621A1 (en) | 1998-10-06 | 2000-04-13 | The Trustees Of Columbia University In The City Of New York | Extracellular novel rage binding protein (en-rage) and uses thereof |
US20030032090A1 (en) * | 1997-05-07 | 2003-02-13 | Schering Corporation, A New Jersey Corporation | Human receptor proteins; related reagents and methods |
ATE458053T1 (de) | 1997-05-07 | 2010-03-15 | Schering Corp | Menschliche toll-like-rezeptorproteine, zugehörige reagenzien und verfahren |
IT1291366B1 (it) * | 1997-05-14 | 1999-01-07 | Angelini Ricerche Spa | Composizione farmaceutica antivirale comprendente acido glicirrizico ed almeno una proteina dotata di attivita' antivirale |
US20030027260A1 (en) * | 1997-10-17 | 2003-02-06 | Genentech, Inc. | Human Toll homologues |
PT1887014E (pt) | 1997-10-17 | 2010-07-05 | Genentech Inc | Homëlogos de toll humana |
ES2137125B1 (es) | 1997-11-18 | 2000-08-16 | Vinyals S A Lab Dr | La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal. |
US6783961B1 (en) | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
IT1299583B1 (it) | 1998-05-19 | 2000-03-16 | Vander Way Limited | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica |
US7151082B2 (en) | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
US6177077B1 (en) | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
TWI221082B (en) | 1999-04-14 | 2004-09-21 | Sumitomo Chemical Co | Pesticidal compositions |
WO2000075358A2 (en) | 1999-06-04 | 2000-12-14 | Millennium Pharmaceuticals, Inc. | Mammalian toll homologues and uses thereof |
US6794132B2 (en) * | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
US7572466B1 (en) * | 1999-10-13 | 2009-08-11 | Health Research, Inc. | Oral immunology using plant product containing a non-enteric pathogen antigen |
GB9927332D0 (en) | 1999-11-18 | 2000-01-12 | Leiv Eiriksson Nyfotek As | Novel antibody and uses thereof |
US6677321B1 (en) * | 1999-12-09 | 2004-01-13 | Bruce Levin | Methods and compositions for treatment of inflammatory disease |
GB0001704D0 (en) | 2000-01-25 | 2000-03-15 | Glaxo Group Ltd | Protein |
EP1275713A4 (en) | 2000-03-31 | 2004-06-30 | Mochida Pharm Co Ltd | BINDING INHIBITOR BETWEEN THE TOLL-TYPE RECEPTOR AND CD14 |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
EP1283849A2 (en) | 2000-05-25 | 2003-02-19 | Schering Corporation | Human receptor proteins; related reagents and methods |
GB0015325D0 (en) | 2000-06-22 | 2000-08-16 | Danionics As | Electrochemical cells |
CA2439852A1 (en) | 2001-03-02 | 2002-09-12 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
CN1235583C (zh) | 2001-03-05 | 2006-01-11 | 特兰斯泰克制药公司 | 用作治疗剂的苯并咪唑衍生物 |
CN1494425B (zh) * | 2001-03-05 | 2011-12-07 | 特兰斯泰克制药公司 | 用作治疗剂的羧酰胺衍生物 |
AU2002255805B2 (en) | 2001-03-15 | 2005-03-24 | North Shore Long Island Jewish Research Institute | Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions |
ITMI20010562A1 (it) | 2001-03-16 | 2002-09-16 | Marco E Bianchi | Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari |
CA2446458A1 (en) | 2001-05-09 | 2002-11-14 | Yale University | Toll/interleukin-1 receptor adaptor protein (tirap) |
WO2002089743A2 (en) | 2001-05-09 | 2002-11-14 | The Regents Of The University Of Michigan | Use of compositions for treating rosacea |
CA2447576C (en) * | 2001-05-15 | 2014-04-08 | North Shore-Long Island Jewish Research Institute | Use of hmg fragments as anti-inflammatory agents |
US7304034B2 (en) * | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
US7220723B2 (en) * | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
JP4823465B2 (ja) | 2001-07-13 | 2011-11-24 | 株式会社シノテスト | ヒトhmg−1に特異的に結合する抗体並びにこの抗体を用いるヒトhmg−1の免疫学的測定方法及び免疫学的測定試薬 |
US20030032674A1 (en) * | 2001-08-13 | 2003-02-13 | Hwang Daniel H. | Use of unsaturated fatty acids to treat severe inflammatory diseases |
BR0212366A (pt) | 2001-09-07 | 2004-07-27 | Univ Boston | Método e composição para tratar distúrbios associados com o complexo imune |
JP2003088388A (ja) | 2001-09-14 | 2003-03-25 | Herikkusu Kenkyusho:Kk | 新規な全長cDNA |
EP1293566A1 (en) * | 2001-09-17 | 2003-03-19 | Societe Des Produits Nestle S.A. | A soluble toll-like receptor |
WO2003057715A2 (en) | 2001-12-28 | 2003-07-17 | The Regents Of The University Of California | Novel ligand involved in the transmigration of leukocytes . |
ES2373875T3 (es) | 2002-03-05 | 2012-02-09 | Transtech Pharma, Inc. | Derivados de azol mono y bicíclicos que inhiben la interacción de ligandos con rage. |
DE60326453D1 (de) | 2002-07-03 | 2009-04-16 | Ct Cardiologico Monzino S P A | Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung |
GB0226251D0 (en) | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
JP2006506441A (ja) | 2002-11-20 | 2006-02-23 | ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト | 免疫応答を増大させるためのhmgbポリペプチドの使用 |
WO2004046345A2 (en) | 2002-11-20 | 2004-06-03 | Critical Therapeutics, Inc. | Use of hmgb fragments as anti-inflammatory agents |
US20040141948A1 (en) * | 2002-11-20 | 2004-07-22 | Critical Therapeutics, Inc. | Use of HMGB fragments as anti-inflammatory agents |
US7696169B2 (en) * | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
AU2004272607B2 (en) * | 2003-09-11 | 2008-11-06 | Cornerstone Therapeutics Inc. | Monoclonal antibodies against HMGB1 |
WO2005034952A2 (en) | 2003-10-07 | 2005-04-21 | The Feinstein Institute For Medical Research | Isoxazole and isothiazole compounds useful in the treatment of inflammation |
US20080305120A1 (en) | 2004-06-17 | 2008-12-11 | Medimmune, Inc. | Immunogenic Compositions Comprising Hmgb 1 Polypeptides |
WO2006008779A1 (en) | 2004-07-20 | 2006-01-26 | Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione-Istituto Dermopatico Dell'immacolata | Use of hmgb1 for wound healing |
US7470521B2 (en) | 2004-07-20 | 2008-12-30 | Critical Therapeutics, Inc. | RAGE protein derivatives |
GEP20105110B (en) | 2004-08-03 | 2010-11-10 | Transtech Pharma Inc | Rage fusion proteins and their use |
BRPI0514835A (pt) | 2004-09-03 | 2008-06-24 | Creabilis Therapeutics Spa | variante de polipetìdeo de box de domìnio de ligação por alta afinidade de hmbg1 humano e/ou não humano ou de fragmento biologicamente ativo de box-a de hmgb1, molécula de ácido nucléico, uso, composição farmacêutica e dispositivo médico |
CA2585043A1 (en) | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
US8129130B2 (en) | 2004-10-22 | 2012-03-06 | The Feinstein Institute For Medical Research | High affinity antibodies against HMGB1 and methods of use thereof |
WO2007011606A2 (en) | 2005-07-18 | 2007-01-25 | Critical Therapeutics, Inc. | USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS |
CA2628546A1 (en) | 2005-11-09 | 2007-05-18 | Pharmexa A/S | Therapeutic vaccines targeting hmgb1 |
US20080311122A1 (en) | 2005-11-28 | 2008-12-18 | Medimmune, Llc | Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof |
MX349810B (es) * | 2006-09-08 | 2017-08-14 | Abbvie Bahamas Ltd | Proteinas de enlace de interleucina-13. |
US8173405B2 (en) | 2006-12-13 | 2012-05-08 | William Marsh Rice University | Nerolidol, terpene, and terpene deriviative synthesis |
WO2008154638A2 (en) | 2007-06-12 | 2008-12-18 | Board Of Regents, The University Of Texas System | Antagonists of the receptor for advanced glycation end-products (rage) |
-
2004
- 2004-09-10 AU AU2004272607A patent/AU2004272607B2/en not_active Ceased
- 2004-09-10 CA CA2882022A patent/CA2882022A1/en not_active Abandoned
- 2004-09-10 EP EP04788671A patent/EP1668035A2/en not_active Withdrawn
- 2004-09-10 US US10/938,992 patent/US7288250B2/en not_active Expired - Fee Related
- 2004-09-10 CA CA2538763A patent/CA2538763C/en not_active Expired - Fee Related
- 2004-09-10 WO PCT/US2004/029527 patent/WO2005026209A2/en active Application Filing
- 2004-09-10 JP JP2006526305A patent/JP4792392B2/ja not_active Expired - Fee Related
- 2004-09-10 CN CNA2004800332177A patent/CN1878793A/zh active Pending
-
2007
- 2007-09-20 US US11/903,129 patent/US7632500B2/en active Active
- 2007-10-15 US US11/974,923 patent/US20090148453A1/en not_active Abandoned
-
2010
- 2010-10-04 US US12/897,453 patent/US8846047B2/en not_active Expired - Fee Related
-
2011
- 2011-05-27 JP JP2011118559A patent/JP5513441B2/ja not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007527406A5 (ja) | ||
US20230242620A1 (en) | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains | |
US9469689B2 (en) | Therapeutic DLL4 binding proteins | |
JP2009517057A5 (ja) | ||
AU2009279865B2 (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
JP2010502183A5 (ja) | ||
TW201808995A (zh) | 抗il-33抗體和彼之組成物、方法及用途 | |
TW201124427A (en) | IL-1 binding proteins | |
RU2008126242A (ru) | Антитела против глобуломера а бета, их антигенсвязывающие части, соответствующие гибридомы, нуклеиновые кислоты, векторы, клетки-хозяева, способы получения указанных антител, композиции, содержащие указанные антитела, применения указанных антител и способы использования указанных антител | |
RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
RU2007118670A (ru) | Ангиопоэтин-2-специфические связывающие агенты | |
JP2005528914A5 (ja) | ||
EP2944654A1 (en) | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains | |
US20110223176A1 (en) | Basigin binding proteins | |
JP2005535562A5 (ja) | ||
JP2017524362A5 (ja) | ||
US20200369774A1 (en) | Il-6r antibody and antigen binding fragment thereof and medical use | |
IL186509A (en) | Reagents that bind ccx-ckr2 | |
JP2019513004A5 (ja) | ||
WO2016061632A1 (en) | Fn14-binding proteins and uses thereof | |
JPWO2020130138A1 (ja) | 抗preS1抗体およびその用途 | |
WO2022238481A1 (en) | Antibodies | |
US20190225680A1 (en) | Tenascin Epitope and Antibodies Thereto | |
JP2023547167A (ja) | コロナウイルススパイクタンパク質に特異的な抗体及びその用途 | |
JPWO2019173503A5 (ja) |